Malignant Hypertension: Current Perspectives and Challenges.
Boulestreau R, van den Born BH, Lip GYH, Gupta A.
J Am Heart Assoc. 2022 Apr 5;11(7):e023397. doi: 10.1161/JAHA.121.023397. Epub 2022 Mar 15.
Malignant hypertension: does this still exist?
Domek M, Gumprecht J, Lip GYH, Shantsila A.
J Hum Hypertens. 2020 Jan;34(1):1-4. doi: 10.1038/s41371-019-0267-y. Epub 2019 Oct 21.
Malignant Hypertension:A Systemic Cardiovascular Disease: JACC Review Topic of the Week.
Boulestreau R, Śpiewak M, Januszewicz A, Kreutz R, Guzik TJ, Januszewicz M, Muiesan ML, Persu A, Sarafidis P, Volpe M, Zaleska-Żmijewska A, van den Born BH, Messerli FH.
J Am Coll Cardiol. 2024 Apr 30;83(17):1688-1701. doi: 10.1016/j.jacc.2024.02.037.
Pharmacological management of malignant hypertension.
Lewek J, Bielecka-Dąbrowa A, Maciejewski M, Banach M.
Expert Opin Pharmacother. 2020 Jul;21(10):1189-1192. doi: 10.1080/14656566.2020.1732923. Epub 2020 Feb 26.
Malignant Hypertension Revisited-Does This Still Exist?
Shantsila A, Lip GYH.
Am J Hypertens. 2017 Jun 1;30(6):543-549. doi: 10.1093/ajh/hpx008.
Management of hypertensive crisis: British and Irish Hypertension Society Position document.
Kulkarni S, Glover M, Kapil V, Abrams SML, Partridge S, McCormack T, Sever P, Delles C, Wilkinson IB.
J Hum Hypertens. 2023 Oct;37(10):863-879. doi: 10.1038/s41371-022-00776-9. Epub 2022 Nov 22.
[Malignant hypertension: A bright future].
Boulestreau R, Cremer A, Lorthioir A, Rubin S, Tharaux PL, Persu A, Halimi JM, Gosse P.
Presse Med. 2019 Dec;48(12):1439-1444. doi: 10.1016/j.lpm.2019.07.007. Epub 2019 Aug 27.
The pharmacological management of malignant hypertension.
Gosse P, Boulestreau R, Brockers C, Puel C, Rubin S, Cremer A.
J Hypertens. 2020 Nov;38(11):2325-2330. doi: 10.1097/HJH.0000000000002547.
Malignant hypertension.
Kincaid-Smith P.
J Hypertens. 1991 Oct;9(10):893-9.
Malignant hypertension causing severe chorioretinopathy.
Basilious A, McInnis RL, Juncal VR.
Can J Ophthalmol. 2023 Aug;58(4):e160. doi: 10.1016/j.jcjo.2022.11.009. Epub 2022 Dec 5.
